Collaboration and Licensing Revenue - Summary of Deferred Revenue by Collaborator, Current Year (Details) - USD ($) $ in Thousands		Dec. 31, 2019	Dec. 31, 2018
Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			$ 54,323
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 50,593
ZIOPHARM Oncology, Inc. | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			1,214
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		0 years
ZIOPHARM Oncology, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 0
Oragenics, Inc. | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			1,785
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		4 years 4 months 24 days
Oragenics, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 2,864
Intrexon Energy Partners, LLC | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			10,267
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		4 years 2 months 12 days
Intrexon Energy Partners, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 8,362
Intrexon Energy Partners II, LLC | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			14,060
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		4 years 10 months 24 days
Intrexon Energy Partners II, LLC | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 12,843
Fibrocell Science, Inc. | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			17,519
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		4 years 10 months 24 days
Fibrocell Science, Inc. | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 17,697
Harvest Start-Up Entities | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	[1]		7,644
Harvest Start-Up Entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)	[1]	5 years 2 months 12 days
Harvest Start-Up Entities | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue	[1]	$ 6,993
Other | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue			$ 1,834
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Summary of Deferred Revenue by Collaborator [Line Items]
Average Remaining Performance Period (Years)		2 years 9 months 18 days
Other | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Upfront and Milestone Payments
Summary of Deferred Revenue by Collaborator [Line Items]
Deferred revenue		$ 1,834

[1] As of December 31, 2019 and 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes Exotech Bio, AD Skincare, and Thrive Agrobiotics.